Merck Receives Positive EU CHMP Opinion for PREVYMIS® for Prevention of CMV Disease in High-Risk Adult Kidney Transplant Recipients and Extended 200-Day Dosing in Adult HSCT Recipients at Risk for Late CMV Infection and DiseaseBusiness Wire • 10/17/23
FDA Approves KEYTRUDA® (pembrolizumab) for Treatment of Patients With Resectable (T≥4 cm or N+) NSCLC in Combination With Chemotherapy as Neoadjuvant Treatment, Then Continued as a Single Agent as Adjuvant Treatment After SurgeryBusiness Wire • 10/16/23
European Commission Approves KEYTRUDA® (pembrolizumab) as Adjuvant Treatment for Adults With Non-Small Cell Lung Cancer at High Risk of Recurrence Following Complete Resection and Platinum-Based ChemotherapyBusiness Wire • 10/16/23
Worried About a Recession? This Pharma Stock Could Be the Safe Haven You Need.InvestorPlace • 10/16/23
Merck Receives Positive EU CHMP Opinion for KEYTRUDA® (pembrolizumab) Plus Chemotherapy as First-Line Treatment for HER2-Negative Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma Expressing PD-L1 (CPS ≥1)Business Wire • 10/13/23
Merck reports positive results for blockbuster cancer drug in treating non-small cell lung cancerMarket Watch • 10/10/23
Merck Highlights Innovative Oncology Portfolio and Pipeline at ESMO Congress 2023 Underscoring Commitment to Advancing Cancer Research and Improving Patient Outcomes Across Multiple Stages of DiseaseBusiness Wire • 10/10/23
Merck Announces Pivotal KEYNOTE-671 Trial Meets Dual Primary Endpoint of Overall Survival (OS) in Resectable Stage II, IIIA or IIIB Non-Small Cell Lung Cancer (NSCLC)Business Wire • 10/10/23
Merck Presents New MAVENCLAD® (Cladribine Tablets) Data Highlighting Sustained Reduction in NfLs and Benefit of Early InitiationBusiness Wire • 10/10/23
Merck Launches New Collaboration with United Nations-Guided Global Initiative on Ageing to Support CarersBusiness Wire • 10/05/23